Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tralesinidase alfa - BioMarin Pharmaceutical

Next Previous
Drug Profile

Tralesinidase alfa - BioMarin Pharmaceutical

Alternative Names: Alpha-N-acetyglucosaminidase-insulin-like-growth-factor-2 fusion protein; AX-250; BMN 250; NAGLU-IGF2 fusion protein; TA-ERT - BioMarin Pharmaceutical

Latest Information Update: 15 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioMarin Pharmaceutical
  • Class Acetylglucosaminidases; Recombinant fusion proteins
  • Mechanism of Action Alpha N acetyl D glucosaminidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis III
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Mucopolysaccharidosis III

Most Recent Events

  • 07 May 2025 Spruce plans to launch Tralesinidase alfa in Latin America, Turkey, Asia, and other international markets
  • 06 May 2025 Tralesinidase alfa - BioMarin Pharmaceutical receives Fast Track designation for Mucopolysaccharidosis III [Intracerebral] (In children, In infants) in USA prior to May 2025
  • 06 May 2025 Tralesinidase alfa - BioMarin Pharmaceutical receives Priority Medicine (PRIME) status for Mucopolysaccharidosis III in European Union prior to May 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top